Patient recruitment remains to be one of the biggest, and most costly, bottlenecks in clinical development. While the most commonly accepted recruitment mainstays are investigative site patient databases and advertising, industry averages reveal that more than 80% of clinical trials are delayed because of poor enrollment. So it stands to reason that the mainstay recruitment practices may require retooling or additional tactics to meet the demand for qualified participants.
Industry insiders admit there is no one answer to solve this ongoing challenge, and with the increased complexity of clinical trial design, the trend toward more targeted patient populations and the growing movement toward emerging markets for clinical trials…
Evaluating Sites and Investigators by Phase
Gretchen Goller. Patient Recruitment and Compliance Strategist, Operations, Sanofi-Aventis, a global pharmaceutical company that discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. For more information, visit sanofi-aventis.us.
Dr. Jamil Hussain. Senior VP, Clinical Development, Citeline Inc., a provider of real-time R&D intelligence to the pharmaceutical industry, covering global clinical trial, investigator, and drug intelligence. For more information,
Jason Richardson. President, Cutting Edge Information, a provider of innovative, implementable research and consulting to the pharmaceutical, biotechnology, and medical-devices industries. For more information, visit cuttingedgeinfo.com.